Novocure Ltd. (NASDAQ:NVCR) on Thursday reported topline results from its Phase 3 TRIDENT study.
The data showed that starting Tumor Treating Fields (TTFields) therapy during chemoradiation did not significantly improve overall survival compared with initiating the therapy during the maintenance phase in patients with newly diagnosed glioblastoma (GBM).
The study evaluated an Early Start Arm, in which TTFields therapy began alongside chemoradiation, against a Maintenance Start Arm, where treatment was initiated later during maintenance therapy.
Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing cancer cells to die.
Read Next
